Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial of AB928 in healthy volunteers

Next Previous
X
Search
Trial Profile

A phase 1 trial of AB928 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etrumadenant (Primary)
  • Indications Breast cancer; Cancer; Colorectal cancer; Gastrointestinal cancer; Oesophageal cancer; Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Arcus Biosciences

    • Most Recent Events

    • 19 Dec 2018 Results published in the Investigational New Drugs
    • 09 May 2018 According to an Arcus Biosciences media release, initial data from this trial were presented at the AACR Annual Meeting in April.
    • 17 Apr 2018 According to an Arcus Biosciences media release, complete results from this trial, including pharmacodynamic data for the 200 mg BID (with food) dosing cohort, will be released following the unblinding of data in mid-2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top